Article Text

Download PDFPDF
  1. Terence O'Brien1,
  2. Anna Patten2,
  3. Francesco Bibbiani3,
  4. Haichen Yang3,
  5. Betsy Williams3,
  6. Antonio Laurenza3
  1. 1 The Royal Melbourne Hospital, The University of Melbourne, Australia
  2. 2 Eisai Ltd, UK
  3. 3 Eisai Inc, USA


Purpose A post hoc analysis evaluated the efficacy and tolerability of perampanel across four Phase III studies in patients with secondarily generalised (SG) or primary generalised tonic-clonic (PGTC) seizures.

Method All studies involved patients aged ≥12 years. Studies 304 (n=388) and 305 (n=386) evaluated perampanel 8 or 12 mg/day or placebo. Study 306 (n=706) evaluated perampanel 2, 4, or 8 mg/day or placebo. These studies had a 19-week double-blind phase (6-week titration; 13-week maintenance). Study 332 (n=164) evaluated perampanel up to 8 mg/day or placebo (17-week double-blind phase; 4-week titration, 13-week maintenance). Full Analysis Set (FAS) included patients who had SG or PGTC seizures and received perampanel 8 mg/day.

Results FAS included 492 patients (mean age 31.7 years). Compared with placebo, perampanel conferred a greater median percent reduction in PGTC/SG seizure frequency per 28 days (−24.6% vs. −65.5%; p<0.0001), greater 50% responder rate (37.8% vs. 61.8%; p<0.0001) and higher rate of seizure freedom from PGTC/SG (12.6% vs. 26.9%). Compared with placebo, most common adverse events with perampanel were dizziness (5.9% vs. 28.6%), somnolence (5.9% vs. 13.4%), and headache (10.6% vs. 12.2%).

Conclusion Perampanel reduced generalised tonic-clonic seizure frequency, whether primary or SG, and was well tolerated.

Funded by Eisai Inc.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.